Novo Raises Forecast as Wegovy Pill Fuels Sales

Summary

Novo Nordisk reported better-than-expected Q1 earnings driven by Wegovy pill sales in the US, leading to a slight raise in full-year guidance. However, revenues and profit are still expected to decline for the year, and the company faces intense competition from Eli Lilly. The impact on the Danish economy remains a concern, but there is optimism given Novo's continued profitability and job creation.

• Novo Nordisk reports Q1 earnings lifted by Wegovy pill sales in the US.
• Company raises full-year guidance for adjusted sales and operating profit.
• Operating margins came in at 62%, well above the 43% estimate.
• Novo still expects revenue and profit to decline for the year.
• Intense competition with Eli Lilly is a major challenge.
• Novo is betting on lower prices and the Wegovy pill to regain market share.
• The launch of the Wegovy pill in January is seen as encouraging.
• Novo's fortunes have a significant impact on the Danish economy.